Exposure-response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors.

CPT Pharmacometrics Syst Pharmacol · 2022 · PMC9124358 · PMID 34648693

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Overall, there appeared to be a clear trend showing a reduction in platelet count over time with molibresib treatment (Figure S2 ).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.